New pi3k/akt/mtor inhibitors and pharmaceutical uses thereof

A method of prevention and/or treatment of tuberous sclerosis comprising administering a pharmaceutical acceptable amount of a compound having formula (I):

• wherein:
• X is O or S;
• R1, R2, R3 and R4 are independently selected from the group consisting of:
• H, (C1-C10)alkyl, (C1-C10)alkoxyl, (C2-C10)alkenyl, (C2-C10)alkynyl, OH, a fluorine atom, a bromine atom, a iodine atom, O(C1-C10)alkylene-NHCO(C1-C10)alkylene-(C5-C10)heterocycloalkyl and O(C1-C10)alkylene-NH—CS—NH—R″ with R″ being:
• wherein:
• R2 and R3 may form together with the carbon atoms to which R2 and R3 are attached to form a (C6-C10)aryl group;
• and
• R″ and the (C5-C10)heterocycloalkyl are optionally substituted by at least one substituent selected from OH and ═O;
• EWG is chosen selected from the group consisting of:
• NO2, CHO, COR, CN, CN—OH, CONHR, CONRR′ and COOR;
• R and R′ being independently from each other chosen from (C1-C10)alkyl groups;
• R5 is a (C6-C10)aryl, a (C5-C10)heteroaryl group, a (C3-C10)cycloalkyl or a (C3-C10)heterocycloalkyl group;
• said aryl and heteroaryl being optionally substituted by at least one substituent independently chosen from halogen, (C1-C10)alkoxyl and nitro;
• R5 being different from the group:
• and wherein when EWG is COOMe, one of R1, R2, R3 or R4 is different from H;
• and provided that the compound of formula (I) is not:
• or its pharmaceutically acceptable salts, hydrates or hydrated salts or its polymorphic crystalline structures, racemates, diastereomers or enantiomers;
• to a patient in need thereof.